Clinical trials: Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS)
Safety, Tolerability, and Pharmacodynamic Exploration of Orelabrutinib in Patients With Amyotrophic Lateral Sclerosis (ALS)
This is a single-center, open-label, dose-escalation, investigator-initiated pilot study to evaluate the safety, tolerability, dose-limiting toxicity (DLT), and pharmacodynamic signals of orelabrutinib in patients with…
- Trial name
- NCT07875972
- Testing
- Orelabrutinib
- Volunteers
- 12 people
- Sponsor
- Liu Qing
Spinal Cord Injury (SCI), Amyotrophic Lateral Sclerosis (ALS)
Brain and Nerve Stimulation for Hand Muscles in Spinal Cord Injury and ALS
Most neurological injuries such as spinal cord injuries (SCI) and amyotrophic lateral sclerosis (ALS) spare a portion of nerve circuitry.
- Trial name
- NCT02469675
- Testing
- Transcranial magnetic stimulation, Median nerve stimulation, Cervical transcutaneous stimulation
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Bronx VA Medical Center
Amyotrophic Lateral Sclerosis
A New Eye-based Communication Device for ALS Patients
Eighteen ALS patients will be trained to control a new communication device (Eye On Line: EOL) that permit over smooth eye movements to generate digits, letters, words or drawing at will.
- Trial name
- ELY-SLA (NCT02313402)
- Testing
- EOL (Eye On Line)
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Clinical Characteristics, Natural History, Health Care Measures, and Genetic Screening in Patients With ALS
Patients with sporadic ALS (sALS), which refers to those without a family history of ALS, are typically not subjected to genetic investigations as part of their standard care. Therefore, their mutation status is often unknown.
- Trial name
- ID-ALS (NCT05852405)
- Where
- Germany
- Volunteers
- 2,000 people
- Sponsor
- Ambulanzpartner Soziotechnologie APST GmbH
Neuromuscular Diseases
Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease that causes the death of 30,000 affected individual every year.
- Trial name
- NCT03272802
- Testing
- Edaravone, Riluzole
- Where
- Iran
- Volunteers
- 20 people
- Sponsor
- Isfahan University of Medical Sciences
Amyotrophic Lateral Sclerosis
sCD163 in ALS Patients
Amyotrophic lateral sclerosis (ALS) is a fatal disease with progressive muscle weakness leading to severe disability and eventually death.Since the diagnosis relies on clinical features and electromyographic abnormalities, which…
- Trial name
- NCT02325375
- Testing
- lumbar puncture for spinal fluid and blood sample
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- University of Aarhus
Amyotrophic Lateral Sclerosis, Dyspnea
The Reliability and Validity of Turkish Version of ''The Dyspnea-ALS-Scale (DALS-15)"
The Dyspnea-ALS-Scale (DALS-15) is a uni-dimensional scale to measure dyspnea in patients with Amyotrophic Lateral Sclerosis. It can be easily and rapidly applied.
- Trial name
- NCT04305639
- Where
- Turkey (Türkiye)
- Volunteers
- 52 people
- Sponsor
- Istanbul Medeniyet University
Amyotrophic Lateral Sclerosis, Dietary Habits
Evaluating the Potential of the Diet as Disease Modifier in Amyotrophic Lateral Sclerosis (JERN_ALS)
The proposed observational trial will collect substantial data concerning dietary intake documented by ALS patients complemented by the analysis of fatty acid distribution in erythrocyte lipids.
- Conditions
- Amyotrophic Lateral Sclerosis, Dietary Habits, Disorder of Fatty Acid Metabolism
- Trial name
- JERN_ALS (NCT02572479)
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- University of Jena
Amyotrophic Lateral Sclerosis, Progressive Muscular Atrophy
Study of ALS Reversals 2: Genetic Analyses
The purpose of this study is to try to understand why reversals of amyotrophic lateral sclerosis (ALS) and primary muscular atrophy (PMA) take place.
- Trial name
- StAR2 (NCT03464903)
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Duke University
Amyotrophic Lateral Sclerosis
The NO-ALS Study: A Trial of Nicotinamide/Pterostilbene Supplement in ALS.
Amyotrophic lateral sclerosis (ALS) is a serious rapidly progressive disease of the nervous system. The average survival from the time of diagnosis is 3 years. Apart from Riluzole, there is no effective treatment.
- Trial name
- NCT04562831
- Testing
- EH301 (Nicotinamide Riboside/Pterostilbene)
- Where
- 9 sites in Norway
- Volunteers
- 380 people
- Sponsor
- Haukeland University Hospital
Amyotrophic Lateral Sclerosis
FUNCtion ALS: Aiming to Restore UNC13A Function in People Living With ALS
The FUNCtion Amyotrophic Lateral Sclerosis (ALS) trial is a randomized, double-blind, placebo-controlled Phase 1/2 trial to evaluate the safety and tolerability of TRCN-1023 in adults living with ALS.
- Trial name
- FUNCtion ALS (NCT07674667)
- Testing
- TRCN-1023
- Where
- 6 sites in Germany, Netherlands and 1 more
- Volunteers
- 30 people
- Sponsor
- Trace Neuroscience, Inc.
ALS
Talampanel for Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to assess the efficacy, tolerability and safety of oral administration of talampanel compared to a placebo in subjects with ALS.
- Trial name
- ALS (NCT00696332)
- Testing
- Talampanel
- Where
- 24 sites in United States, Belgium and 8 more
- Volunteers
- 559 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Amyotrophic Lateral Sclerosis
Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intrathecal Injection for ALS
This trial will study the safety and efficacy of intrathecal injection of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells for the treatment of amyotrophic lateral sclerosis
- Trial name
- NCT05003921
- Testing
- cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
Amyotrophic Lateral Sclerosis (ALS)
Do Video Recordings of Multidisciplinary Clinics Improve Quality of Life for People With ALS and Their Caregivers?
Amyotrophic lateral sclerosis (ALS) is a fatal, rare neurodegenerative disease affecting 30,000 people in the United States. The gold standard of care for people with ALS is multidisciplinary clinics (MDC).
- Trial name
- VITALS (NCT07454733)
- Testing
- Video recording, Notes Instruction
- Where
- 7 sites in United States
- Volunteers
- 800 people
- Sponsor
- Trustees of Dartmouth College
ALS (Amyotrophic Lateral Sclerosis)
Safety and Tolerability Study of CTx1000 In Participants With Amyotrophic Lateral Sclerosis
This clinical study is in participants with Amyotrophic Lateral Sclerosis and is designed to evaluate the safety and tolerability of the gene therapy CTx1000.
- Trial name
- KOANEWA (NCT07401121)
- Testing
- AAV9 Gene therapy
- Where
- Australia
- Volunteers
- 15 people
- Sponsor
- Celosia Therapeutics Pty Ltd
Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis
Digital Smartwatch Measurements as Potential Biomarkers for Remote Disease Tracking in ALS
This observational study will use new smartwatch technology to continuously and remotely monitor the health of ALS patients and healthy controls over time. This information will be used to develop digital biomarkers for ALS.
- Conditions
- Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis, Muscular Atrophy, Progressive, Frontotemporal Dementia
- Trial name
- NCT05830214
- Where
- Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Alberta
Amyotrophic Lateral Sclerosis (ALS)
Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to determine if oral treatment with ONO-2506PO in patients diagnosed with ALS, who have had onset of muscle weakness within 14 months of randomization, could lead to the slowing of decline in…
- Trial name
- NCT00403104
- Testing
- ONO-2506PO
- Where
- 26 sites in Austria, Belgium and 6 more
- Volunteers
- 420 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Amyotrophic Lateral Sclerosis
Effects of Gastrostomy on Amyotrophic Lateral Sclerosis
Results about effects of symptomatic treatment on QoL appears conflicting in ALS patients. Moreover no clear effects of gastrotomy have be shown on survival.
- Trial name
- NCT00337402
- Where
- France
- Volunteers
- 380 people
- Sponsor
- University Hospital, Clermont-Ferrand
Amyotrophic Lateral Sclerosis
Early Feasibility Study of the MyoRegulator® for Treatment of ALS
This is a single-center, single-arm, open-label study aiming to assess the safety and feasibility of the MyoRegulator® device when used to treat individuals with amyotrophic lateral sclerosis (ALS).
- Trial name
- ALSEFS (NCT06165172)
- Testing
- MyoRegulator®
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- PathMaker Neurosystems Inc.
ALS (Amyotrophic Lateral Sclerosis)
T-regulatory Cells in ALS
This study is a randomized, placebo-controlled, phase 2a trial to study the biological activity, safety, and tolerability of regulatory T Lymphocytes (Tregs) taken and expanded outside of the body and returned back to the same…
- Trial name
- Tregs in ALS (NCT04055623)
- Testing
- Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- The Methodist Hospital Research Institute